Sanjivani Paranteral Ltd vs Venus Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Sanjivani Paranteral Ltd is ₹ 133.75 as of 18 May 15:30 . The P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 35.2 on March 2025 . This represents a CAGR of 11.33% over 2 yearsThe P/E Ratio of Venus Remedies Ltd changed from 5.5 on March 2021 to 8.8 on March 2025 . This represents a CAGR of 9.86% over 5 years The Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 284.8 crore on March 2025 . This represents a CAGR of 27.45% over 2 yearsThe Market Cap of Venus Remedies Ltd changed from ₹ 338.91 crore on March 2021 to ₹ 400.47 crore on March 2025 . This represents a CAGR of 3.39% over 5 years The revenue of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 13.81 crore as compare to the Dec '25 revenue of ₹ 22.36 crore. This represent the decline of -38.24% The revenue of Venus Remedies Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 182.78 crore. This represent the decline of -100% The ebitda of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 2.17 crore as compare to the Dec '25 ebitda of ₹ 4.13 crore. This represent the decline of -47.46% The ebitda of Venus Remedies Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 40.04 crore. This represent the decline of -100% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 0.55 crore over 8 quarters. This represents a CAGR of -43.29% The net profit of Venus Remedies Ltd changed from ₹ 1.22 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Venus Remedies Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

About Venus Remedies Ltd

Incorporated in 1989 Venus Remedies Limited, formerly known as Venus Glucose Pvt Ltd, was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited.
The Company was promoted and managed by Chaudhary & Family.
The Company is one of the handful player in pharmaceutical sector to launch injectables globally.
It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). At present, Venus focuses on specialized therapeutic areas including anti-infectives (antibiotics), oncology, neurology, pain management, and skin and wound care.
In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc. The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana.

FAQs for the comparison of Sanjivani Paranteral Ltd and Venus Remedies Ltd

Which company has a larger market capitalization, Sanjivani Paranteral Ltd or Venus Remedies Ltd?

Market cap of Sanjivani Paranteral Ltd is 164 Cr while Market cap of Venus Remedies Ltd is 1,281 Cr

What are the key factors driving the stock performance of Sanjivani Paranteral Ltd and Venus Remedies Ltd?

The stock performance of Sanjivani Paranteral Ltd and Venus Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanjivani Paranteral Ltd and Venus Remedies Ltd?

As of May 18, 2026, the Sanjivani Paranteral Ltd stock price is INR ₹133.75. On the other hand, Venus Remedies Ltd stock price is INR ₹958.7.

How do dividend payouts of Sanjivani Paranteral Ltd and Venus Remedies Ltd compare?

To compare the dividend payouts of Sanjivani Paranteral Ltd and Venus Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.